Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
VITAMIN B12 Fuel your body with vitamin B12, which plays a key role in utilizing fats and carbohydrates for energy and assisting in the growth of red blood cells, nerve cells, and proteins
The GLP-1 Update for Women in Midlife: Whats Changed, Whats New, and Whats Next New research on GLP-1 medications, hormone therapy, visceral fat, metabolic disease, medication interactions, and what emerging treatments may mean for women in menopause
This is a research blend of two peptides: CJC-1295 without DAC (Mod GRF 1-29), a 29-amino-acid analogue, and Ipamorelin, a selective pentapeptide
Doctors aim for surgical margins of 5 to 10 millimeters around the lesion
PMC 6145203